This message contains images. If you don't see images, click here to view.
Advertise in this news brief.



Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit |  Histology Marketplace:     

Home   History   Meeting Calendar   Career Center   Certification   Contact Us    



 




NSH NEWS

NSH Social Ugly Christmas Sweater Contest
NSH
Deck the halls with ugly sweaters this holiday season. NSH is giving you a chance to win a VISA Gift Card by posting a photo of you in your Ugliest Christmas Sweater. Post your photos in the NSH Facebook Group or Twitter: @NS4Histotech and the favorite ugliest sweater will win. 'Tis the season to rock those ugly sweaters, so have fun and good luck! The contest starts Dec. 17, and the winner will be announced Dec. 23.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




TOP STORIES


Why do tumors become resistant to chemotherapy?
Science Codex
A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance," but Manel Esteller, director of epigenetics and cancer biology at the Bellvitge Biomedical Research Institute, ICREA researcher, and professor of genetics at the University of Barcelona, describes in The Journal of The National Cancer Institute the existence of epigenetic differences that explain the lack of response of the tumor recurs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SPONSORED CONTENT


New means of growing intestinal stem cells unlocked
Bioscience Technology
Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Toronto researchers: Recurring colon cancer deactivated using drug that 'wiped out the ability of cells to make new tumors'
National Post
Canadian scientists believe they have found the "Achilles heel" of colon cancer stem cells, which appear to be responsible for the recurrence of the disease in many patients who have gone into remission after treatment. Researchers at Toronto's University Health Network have used an experimental drug to disable a gene that regulates these stem cells, which are thought to initiate the development of colon cancer, one of the top-three cancer killers of Canadians.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  Stellaris RNA FISH Probes

Stellaris RNA FISH is a new research technology that enables direct detection, localization and quantification of RNA. The low cost per assay, simple protocol, and the ability to localize mRNA and lncRNA to organelles and cellular structures provides obvious benefits for life science research. Custom and catalogued probes sets available. MORE
 


Male breast cancer treated with more masectomies
Oncology Nurse Advisor
Breast cancer is treated differently in men than in women, and men with breast cancer undergo mastectomy more often than women with the disease do. Although locally advanced female breast cancer is commonly treated with radiation, this new study found that radiation is used less in male disease. Researchers from the University of Colorado Cancer Center in Denver examined data from 4,276 cases of male breast cancer and 718,587 cases of female breast cancer. Their data came from the U.S. Surveillance, Epidemiology, and End Results Program database, which has collected cancer statistics since 1973 and includes tumor type, demographics, treatment, and outcome information for about 28 percent of the U.S. population.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




New family of proteins linked to major role in cancer
Medical Xpress
Scientists have described a new family of proteins that appear to play a key role in cancer and might be targets for future cancer drugs. A major new study in the journal Nature sets out the structure of the new family, called glutamate intramembrane proteases — the founding member of which plays a critical role in transforming healthy cells into cancer cells. The research, funded by Cancer Research U.K. and conducted by scientists at The Institute of Cancer Research, London, defined the structure of a protein called Rce1 and established it as the first known member of a whole new protein family.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
Looking for similar articles? Search here, keyword PROTEINS.


  PRODUCT SHOWCASES
ergoCentric Laboratory Seating

Visit LabStorage System’s updated website to view details about this new laboratory seating with specially formulated Infection Control coating. Non-porous and easily disinfected, this moisture proof coating is anti-bacterial, anti-fungal and stain resistant. more
Spring Bioscience - BRAF V600E


Spring Bioscience is leading the research industry by pioneering novel, next generation antibodies that can differentiate mutant and normal protein, enabling pathologists to see relevant mutations within their cellular context. Having already released Exon19 and EGFR L858R for exclusive use by Ventana Medical Systems, Spring Bioscience has launched BRAF V600E.
Click here to find out more.
Reduce Cost with Same Quality

GBI Labs produces the largest selection of secondary detection kits. We provide free samples to 1st time users. Staining with our kits results in similar or better sensitivity than other detection kits on the market. Some 110mL kits cost as little as $700.00 and 18 ml kit > $300.00.


IN THE NEWS


New biomarkers improve prostate cancer diagnostics
Medical Xpress
New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely — thereby helping avoid unnecessary operations. Does the patient have cancer of the prostate gland, commonly called prostate cancer? A question like this is difficult for physicians to answer. Up to now, they have been dependent on clues provided by the prostatespecific antigen PSA. If the prostate gland is attacked by cancer, it releases more of this protein into the bloodstream. However, this test has a weakness: it is very imprecise.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Cell 'arms' reach out and pull early embryo into shape
BioNews
Time-lapse imaging has been used to track the way that cells organize themselves to form an early mouse embryo. "Our findings reveal a completely unanticipated mechanism regulating the earliest stages of embryo development," said Dr. Nicolas Plachta, lead researcher for the study, which was carried out at Monash University's Australian Regenerative Medicine Institute. After an egg is fertilised, it undergoes a series of divisions to produce relatively round cells. At the eight-cell stage, cells become elongated and flatten their membranes against each other, before regaining some slight roundness and continuing to divide.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Team finds potential cause for deadly breast cancer relapse (Medical Xpress)
Research targets parasitic worm disease (Iowa State University via Medical Xpress)
Chemotherapy: When intestinal bacteria provide reinforcement (Science Codex)
Biologists ID new cancer weakness (MIT News)
Scientists develop laser-powered compact X-ray device (R&D Magazine)

Don't be left behind. Click here to see what else you missed.


Aging cells share features with cancer
Ars Technica
The older we get, the higher our risk of cancer. With age, we accumulate exposure to environments and chemicals that increase the risk of acquiring cancer-causing mutations. But the danger doesn't increase in a linear manner, and we know little about why there is such a dramatic increase with aging. Accumulated damage isn’t the only thing going on as we age. The body’s cells also go through a process called senescence. Chief among the changes that come with senescence are alterations to the epigenome, the proteins and chemical modifications that are attached to our DNA. These epigenetic changes can influence which genes are active in different tissues.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Afatinib superior to chemotherapy for EGFR-mutated NSCLC
The Oncology Report
The oral EGFR blocker afatinib was superior to standard chemotherapy at prolonging progression-free survival in patients with advanced nonsmall-cell lung cancers that harbor EGFR mutations, according to a report in the Journal of Clinical Oncology. Patients who received afatinib in this international, industry-sponsored phase-III clinical trial also showed statistically significant and clinically meaningful improvements in lung cancer symptoms and a higher treatment response rate than did those who received a regimen of cisplatin plus pemetrexed, which is widely considered to be the optimal combination chemotherapy, said Dr. Lecia V. Sequist of Massachusetts General Hospital and Harvard Medical School, Boston, and her associates.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 

Under the Microscope
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642   
Contribute news

This edition of Under the Microscope was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Dec. 4, 2013
Nov. 27, 2013
Nov 26, 2013 blast
Nov. 20, 2013



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063